Rabbit Recombinant Monoclonal EGR1 antibody. Suitable for WB, ICC/IF, IHC-P and reacts with Human samples. Cited in 16 publications.
View Alternative Names
KROX24, ZNF225, EGR1, Early growth response protein 1, EGR-1, AT225, Nerve growth factor-induced protein A, Transcription factor ETR103, Transcription factor Zif268, Zinc finger protein 225, Zinc finger protein Krox-24, NGFI-A
- ICC/IF
Lab
Immunocytochemistry/ Immunofluorescence - Anti-Egr1 antibody [EPR15916] (AB194357)
Confocal image showing nuclear and weakly cytoplasmic staining on Hela cells.
Immunocytometry/Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HeLa (human cervix adenocarcinoma ) cells labeling Egr1 with ab194357 at 1/200 dilution, followed by Goat anti-rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution. The cells were co-stained with ab7291, a mouse anti-tubulin antibody (1/1000) using ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/1000) as the secondary. Nuclei counterstained with DAPI (blue).
For negative control 1, ab194357 (1 : 200) was used, followed by (ab150120) anti-mouse secondary antibody at 1/1000 dilution. For negative control 2, (ab7291) mouse primary antibody (1/1000) was used followed by (ab150077) anti-rabbit secondary antibody at 1/1000 dilution.
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Egr1 antibody [EPR15916] (AB194357)
Immunohistochemical analysis of paraffin-embedded human thyroid carcinoma tissue labeling Egr1 with ab194357 at 1/250 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/500 dilution. Counter stained with hematoxylin.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
- WB
Supplier Data
Western blot - Anti-Egr1 antibody [EPR15916] (AB194357)
Blocking/Dilution buffer : 5% NFDM/TBST.
All lanes:
Western blot - Anti-Egr1 antibody [EPR15916] (ab194357) at 1/50000 dilution
All lanes:
293T treated with 20% FBS at 20 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 57 kDa
Observed band size: 80 kDa
false
- WB
Lab
Western blot - Anti-Egr1 antibody [EPR15916] (AB194357)
False colour image of Western blot : Anti-Egr1 antibody [EPR15916] staining at 1/10000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab194357 was shown to bind specifically to Egr1. A band was observed at 73 kDa in wild-type HeLa cell lysates with no signal observed at this size in EGR1 CRISPR-Cas9 edited cell line ab274929 (CRISPR-Cas9 edited cell lysate ab274987). The band observed in the CRISPR-Cas9 edited lysate lane below 73 kDa is likely to represent a truncated form of Egr1. This has not been investigated further and the functional properties of the gene product have not been determined. To generate this image, wild-type and EGR1 CRISPR-Cas9 edited HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.
Lanes 1 - 4:
Western blot - Anti-Egr1 antibody [EPR15916] (ab194357) at 1/10000 dilution
Lanes 1 - 4:
Western blot - Anti-Egr1 antibody [EPR15916] - BSA and Azide free (<a href='/en-us/products/primary-antibodies/egr1-antibody-epr15916-bsa-and-azide-free-ab232448'>ab232448</a>) at 1/10000 dilution
Lane 1:
Wild-type HeLa Vehicle Control TNF-a (0ng/mL, 1h) cell lysate at 20 µg
Lane 2:
Wild-type HeLa TNF-a (20ng/mL, 1h) cell lysate at 20 µg
Lane 3:
Western blot - Human EGR1 knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-egr1-knockout-hela-cell-line-ab274929'>ab274929</a>)
Lane 3:
Western blot - Human EGR1 knockout HeLa cell lysate (ab274987)
Lane 3:
EGR1 knockout HeLa Vehicle Control TNF-a (0ng/mL, 1h) cell lysate at 20 µg
Lane 4:
EGR1 knockout HeLa TNF-a (20ng/mL, 1h) cell lysate at 20 µg
Secondary
All lanes:
Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution
Observed band size: 73 kDa
false
Related conjugates and formulations (1)
-
Anti-Egr1 antibody [EPR15916] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Egr1 acts as an immediate-early response gene. It gets rapidly upregulated in response to growth factors stress signals and other extracellular stimuli. As part of the cellular signaling networks Egr1 interacts with other transcription factors to control the expression of genes involved in cell differentiation proliferation and apoptosis. It does not typically form part of a protein complex but may work in concert with other signaling molecules to influence diverse cellular pathways and maintain cellular homeostasis.
Pathways
Egr1 is involved in the MAPK/ERK and PI3K/AKT signaling pathways both key to regulating cellular growth and survival. It functions as a bridging factor that links extracellular signals to transcriptional changes within the nucleus. In the MAPK/ERK pathway Egr1 works alongside proteins like Ras and MEK to promote early gene transcription in response to mitogenic signals. In the PI3K/AKT pathway Egr1 can influence downstream targets reinforcing the pathway's mechanisms in determining cell fate.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (16)
Recent publications for all applications. Explore the full list and refine your search
Journal of Cancer 15:4577-4590 PubMed39006084
2024
Applications
Unspecified application
Species
Unspecified reactive species
Oncology letters 27:240 PubMed38623570
2024
Applications
Unspecified application
Species
Unspecified reactive species
Chinese medical journal 136:1177-1187 PubMed37083129
2023
Applications
Unspecified application
Species
Unspecified reactive species
Journal of translational medicine 21:201 PubMed36932397
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cell death & disease 14:143 PubMed36805440
2023
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in endocrinology 13:883658 PubMed35721731
2022
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 23: PubMed35563324
2022
Applications
Unspecified application
Species
Unspecified reactive species
iScience 24:103067 PubMed34541473
2021
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in oncology 11:699004 PubMed34497759
2021
Applications
Unspecified application
Species
Unspecified reactive species
Aging 13:18515-18526 PubMed34292876
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com